Table 3 Multivariable logistic regression model of predictors of achieving pCRa.

From: Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer

 

OR

(95% CI)

p-value

cT2 stage (ref = cT1)

1.07

(0.95, 1.20)

0.268

Multi-agent NAC (ref = single agent)

1.34

(1.10, 1.62)

0.003

Hormone receptor+ (ref = HR−)

0.38

(0.34, 0.43)

<0.001

Histology (ref = ductal)

Lobular

0.83

(0.67, 1.02)

0.072

Other

0.87

(0.60, 1.27)

0.467

Grade (ref = well-differentiated)

2

1.59

(1.20, 2.11)

0.001

3–4

2.17

(1.64, 2.88)

<0.001

Age category (ref = 18–39)

40–69

0.97

(0.83, 1.14)

0.717

70+

0.73

(0.58, 0.93)

0.011

Race (ref = White)

Black

0.97

(0.81, 1.15)

0.724

Other

1.37

(1.10, 1.71)

0.005

Year of diagnosis (ref = 2013)

2014

1.19

(1.02, 1.40)

0.032

2015

1.25

(1.07, 1.45)

0.005

Charlson Comorbidity Index (ref = 0)

1

0.82

(0.68, 0.99)

0.036

2

0.77

(0.50, 1.17)

0.222

≥3

0.80

(0.42, 1.55)

0.515

  1. pCR pathologic complete response, NAC neoadjuvant chemotherapy.
  2. aAll adjusted variables in the analysis are included in the table.